HRMY
Harmony Biosciences Holdings
NASDAQ: HRMY · HEALTHCARE · BIOTECHNOLOGY
$30.18
-2.31% today
Updated 2026-06-05
Market cap
$1.83B
P/E ratio
12.74
P/S ratio
2.03x
EPS (TTM)
$2.48
Dividend yield
—
52W range
$26 – $41
Volume
0.8M
WallStSmart proprietary scores
53
out of 100
Grade: C
Hold
Investment rating
6.7
Growth
B8.5
Quality
A8.0
Profitability
A6.0
Valuation
B3/9
Piotroski F-Score
Weak
3.4
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$44.36
+46.98%
12-Month target
$22.07
-26.87%
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy4 Buy4 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.37 — safe zone
+ Free cash flow $27.76M — positive
+ Revenue growth 16.60% QoQ
+ Debt/equity 0.23x — low leverage
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $437.86M | $582.02M | $714.73M | $868.45M | $899.11M |
| Net income | $181.47M | $128.85M | $145.49M | $158.69M | $32.49M |
| EPS | — | — | — | — | $2.48 |
| Free cash flow | $144.29M | $219.07M | $218.67M | $347.89M | $27.76M |
| Profit margin | 41.44% | 22.14% | 20.36% | 18.27% | 16.20% |
Peer comparison
Smart narrative
Harmony Biosciences Holdings trades at $30.18. representing a P/E of 12.74x trailing earnings. Our Smart Value Score of 53/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.37, it sits in the safe zone. TTM revenue stands at $899.11M. with profit margins at 16.20%.
Frequently asked questions
What is Harmony Biosciences Holdings's stock price?
Harmony Biosciences Holdings (HRMY) trades at $30.18, on a P/E of 12.7x and a P/S of 2.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Harmony Biosciences Holdings overvalued?
Harmony Biosciences Holdings carries a Smart Value Score of 53/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Harmony Biosciences Holdings (HRMY)?
The 12-month analyst consensus target is $44.36, about 47.0% above the current $30.18. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Harmony Biosciences Holdings's revenue?
Harmony Biosciences Holdings's trailing twelve-month revenue is $899.11M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Harmony Biosciences Holdings's Altman Z-Score is 3.37, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.03x
ROE16.00%
Beta0.97
50D MA$29.85
200D MA$32.56
Shares out0.06B
Float0.05B
Short ratio—
Avg volume0.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—